Dosing for treatment with Anti-fcrh5 / Anti-CD3 bispecific antibodies
TW202626090APending Publication Date: 2026-07-01GENENTECH INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW114132379
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-09-01
- Filing Date
- 2021-10-05
- Publication Date
- 2026-07-01
Abstract
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5) / anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Need to check novelty before this filing date? Find Prior Art